Montelukast Viatris

Montelukast, the active ingredient in Montelukast Viatris, is a leukotriene receptor antagonist presented as an oral dosage form for oral use. It is employed in the maintenance treatment of asthma, relief of allergic rhinitis symptoms, and prevention of exercise‑induced bronchoconstriction in appropriate patients.

GNH USA supplies Montelukast Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on the leukotriene pathway to manage chronic respiratory conditions.

- Asthma: reduces frequency and severity of bronchospasm as part of maintenance therapy. - Allergic rhinitis: alleviates nasal congestion, sneezing and itching. - Exercise‑induced bronchoconstriction: prevents airway narrowing during physical activity.

Montelukast may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Headache: mild to moderate intensity. - Abdominal pain: occasional discomfort. - Cough: transient irritation. - Nausea: occasional upset stomach.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips or throat. - Stevens‑Johnson syndrome: severe skin reactions. - Eosinophilic granulomatosis with polyangiitis: rare vasculitis. - Mood changes: including depression or suicidal thoughts.

Before prescribing Montelukast, consider the following safety measures.

- Neuropsychiatric monitoring: watch for mood changes or suicidal ideation. - Hepatic function: assess liver status in patients with severe impairment. - Hypersensitivity: avoid in individuals with known allergy to the drug. - Pregnancy and lactation: evaluate risk‑benefit as safety data are limited. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Montelukast can interact with other medicines, requiring attention to potential effects.

Major Interactions (Avoid): - Strong CYP3A4 inducers: may reduce Montelukast exposure (e.g., rifampin, carbamazepine). - Phenobarbital: can lower drug levels, diminishing efficacy.

Moderate Interactions (Monitor Closely): - SSRIs or other antidepressants: may increase neuropsychiatric risk. - Antihistamines: possible additive sedation. - Warfarin: monitor INR as occasional alterations reported.